ClinicalTrials.gg
Not yet recruitingNCT07951502BRIDGEUpdated Nov 20, 2026

A Study of a New Induction and Dosing Schedule for Sublocade in Opioid Use Disorder

A Phase 2 interventional study of Buprenorphine extended-release (Sublocade) in Opioid Use Disorder, sponsored by The Smart Clinic. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by The Smart Clinic · Phase 2, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is looking at a new way to start Sublocade, a monthly injectable medicine already approved in Canada for opioid use disorder. Right now, most people start Sublocade with two doses of 300 mg, one month apart. This study is testing a different, more gradual approach: a smaller dose (50 mg) on Day 1, a second small dose (50 mg) on Day 7, and then the regular dose (300 mg) on Day 14.

The study team wants to find out whether this gradual approach helps people transitioning from methadone, or people who have used buprenorphine before, get started on treatment more easily. Everyone in the study follows the same schedule, and no one gets a placebo (an inactive treatment).

Participants will get study visits on Day 1, Day 7, and Day 14, along with short daily check-ins about how they're feeling for about 4 weeks, and some questionnaires about their quality of life and treatment satisfaction. The study is being done at one clinic in Calgary, Alberta.

Read the detailed description

Sublocade (buprenorphine extended-release) is a Health Canada-approved subcutaneous injection for the management of moderate to severe opioid use disorder in adults (DIN 02483084, 100 mg; DIN 02483092, 300 mg). The currently approved induction regimen consists of 300 mg for the first injection and 300 mg for the second injection, administered one month apart, with subsequent monthly maintenance dosing.

This study evaluates a modified induction and titration schedule intended to characterize an alternative approach for patients transitioning from methadone treatment or with prior buprenorphine exposure. Participants receive 50 mg on Day 1, 50 mg on Day 7, and 300 mg on Day 14, using the same approved product and formulation, prepared via partial-volume administration from the 100 mg pre-filled syringe for the Day 1 and Day 7 doses.

The primary objective is to determine the proportion of participants who complete this induction schedule without discontinuation due to withdrawal symptoms or adverse events. Secondary objectives include characterizing daily withdrawal symptom trajectory (via the Subjective Opiate Withdrawal Scale), and changes in Addiction Severity Index, Quality of Life, PROPr health utility, and Treatment Satisfaction scores from baseline to Week 4.

This is a prospective, single-arm, open-label interventional study with no randomization or control arm; outcomes are compared descriptively to existing standard-of-care induction practice as a historical reference. The study is conducted at a single site (The Smart Clinic, Calgary, Alberta) with a planned enrollment of 50-100 adult participants.

02

Conditions studied

  • Opioid Use Disorder

Keywords

  • buprenorphine Sublocade opioid use disorder induction titration extended-release
03

In context

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

This study's planned enrollment of 100 is above the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.

Browse Opioid-Related Disorders studies →

Lead sponsor

This is the only study on the registry with The Smart Clinic as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently receiving methadone treatment, OR active opioid use disorder with prior exposure to buprenorphine
  • Willingness and ability to provide to participate

Exclusion criteria

Exclusion Criteria:

  • No diagnosis of opioid use disorder and no prior buprenorphine exposure
  • Known intolerance or to buprenorphine
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Modified Induction Schedule

    All participants receive buprenorphine extended-release (Sublocade) by subcutaneous injection: 50 mg on Day 1, 50 mg on Day 7, and 300 mg on Day 14.

    Drug: Buprenorphine extended-release (Sublocade)

Interventions

  • DrugBuprenorphine extended-release (Sublocade)

    Sublocade (buprenorphine extended-release), a Health Canada-approved subcutaneous injection (DIN 02483084, 100 mg; DIN 02483092, 300 mg). Administered as 50 mg on Day 1, 50 mg on Day 7, and 300 mg on Day 14.

06

What researchers measure

Primary outcomes

  1. Induction Completion Rate

    Proportion of participants who complete the Day 1, Day 7, and Day 14 dosing schedule without discontinuation due to withdrawal symptoms or adverse events.

    Time frame: Day 14

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — No formal individual participant data (IPD) sharing plan has been established for this study at this time. This is a single-site, investigator-initiated study, and any future decision regarding data sharing would need to account for participant privacy protections under Alberta's Health Information Act and Personal Information Protection Act, as well as the terms of the study's funding agreement with Indivior Canada Inc.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Aug 2027, 8 months later.

Of 61 non-industry phase 2 interventional studies under Opioid-Related Disorders, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 55. This study's planned 8 months is below that.

Counting every sponsor, half of 68 studies reached it within 40 months; a quarter within 23 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Dec 1, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951502
Lead sponsor
The Smart Clinic
Responsible party
Dr. Navneet Singh Khosa (MD, The Smart Clinic) — Principal investigator
First posted
Nov 20, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Navneet Singh Khosa, MD
Contact
nkhosa@smartc.ca
403-769-0111
Ravneet Kaur Sidhu, BSN
Contact
rsidhu@smartc.ca
4037690111
Jospeh Tcherkezian, PHD
study chair · SMART Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion